Protein stimulates key link between nerve cells, suggesting possible target for mental retardation a

UCSF researchers have exposed a single protein that can stimulate the
maturation of the synapses, or junctures, through which nerve cells communicate
a key signal to one another. The discovery reveals a mechanism critical for
supporting brain development, learning and memory and a possible target for
treating mental retardation and nerve damage following stroke and spinal cord
injury.

The finding, reported in the November 17 issue of Science, indicates that the
protein, PSD-95, helps build the physical scaffolding of the synapse that cells
use to transmit the chemical messenger, or neurotransmitter, known as
glutamate, to a target cell.

The protein also matures other aspects of the synapse—enhancing the
clustering of glutamate receptors on the target cells receiving the chemical
messenger, increasing the number and size of the dendritic spines that hold
glutamate receptors, and increasing the number of glutamate neurotransmitters
emitted from the releasing cell.

The results, says senior author David S. Bredt, MD, PhD, UCSF professor of
physiology, indicate that the protein is the cornerstone of physical maturation
for both the pre- and post- synaptic structures that allow glutamate to signal
from one neuron to another.

The findings are provocative, for glutamate, the major excitatory
neurotransmitter in the brain, is the engine behind cellular learning—
including brain development and mental and physical processes. Glutamate is
also thought to be the key to plasticity, the brain’s ability to relearn mental
and physical skills following injury and to adjust to new circumstances. The
neurotransmitter acts by stimulating a receptor on target cells containing a
protein known as the NMDA receptor, which serves to strengthen, or reinforce,
the neural circuits between nerve cells that store memory.

Glutamate enables the brain to develop, language to be learned, a new math
equation to be grasped, tennis to be mastered and walking to be relearned
following a stroke. But without the synapses that allow the chemical signal’s
transmission from one nerve cell to the next, glutamate has no more luck in
communicating its messages than a train has luck in reaching its destination
without tracks to follow.

During synaptic transmission, nerve cells release thousands of
neurotransmitters from their nerve terminals at once. The messengers diffuse
across a synaptic cleft to corresponding receptors on a target cell, and prompt
a response in that cell that is then transmitted to another cell and yet
another, ultimately causing a wave of reaction in the brain.

Some neurotransmitters, such as GABA, carry inhibitory signals, reducing
excitation and anxiety in the brain, and others, such as dopamine and
serotonin, modulate the activity of neural circuits to influence mood and
sleep. The millisecond relay of glutamate to thousands of nerve cells sparks
the brain into high activity.

Mental retardation is associated with a loss of the dendritic spines on
post-synaptic neurons that play a role in receiving glutamate messages. As the
study shows that PSD-95 increases the number and size of these spines, gene
therapy could prove effective in stimulating the growth of the spines and thus
treating the disease. Likewise, using PSD-95 gene therapy to stimulate the
maturation of glutamate receptors could be used to regenerate nerves following
stroke or spinal cord injury.

On the flip side, when nerve cell receptors that receive glutamate become
overactive and thus receive too much glutamate - as occurs following stroke and
in such neurodegenerative diseases as Alzheimer’s disease - brain damage
occurs. Much research is aimed at treating this so-called excito-toxicity by
blocking the glutamate receptor. But identifying a way to disrupt the synapses
that allow communication of glutamate from one nerve cell to another could
provide an alternative way of treating these diseases and, again, the PSD-95
protein might prove an effective target.

The UCSF researchers conducted their study in cultured neurons of the
hippocampus, a brain structure involved in learning and memory. They
over-expressed the PSD-95 protein in their normal location, the post-synaptic
membrane of neurons, at an early stage of glutamate synapse development.

They detected enhanced clustering and activity of glutamate synapse
development, enhanced clustering and activity of glutamate receptors at the
post-synaptic sites and an increase in the number and size of dendritic spines,
which contain the receptors that respond to glutamate neurotransmitters.

More surprisingly, they discovered that PDS-95 stimulates maturation of the
pre-synaptic terminal, which emits neurotransmitters, presumably by reaching
across the synaptic cleft. They also determined the protein increases the
release of glutamate neurotransmitters from the pre-synaptic terminal of the
emitting neuron.

The findings suggest, says Bredt, that during normal conditions clustering of
the protein at the post-synaptic site, which would cause maturation of the
glutamate synapse, may be regulated during development and during learning
processes and plasticity.

The next step in the research, he says, is to try to understand at the
molecular level what the PSD-95 protein targets to promote synaptic maturity
and plasticity.

Co-authors of the study were Alaa El-Din El-Husseini, PhD, UCSF postdoctoral
fellow in physiology, Eric Schnell, BS, a UCSF graduate student in cellular and
molecular pharmacology, Dane M. Chetkovich, MD, PhD, clinical instructor in
neurology and Roger A. Nicoll, PhD, UCSF professor of cellular and molecular
pharmacology.

The study was funded by the National Institutes of Health, the Howard Hughes
Medical Institute and the National Association for Research on Schizophrenia
and Depression.